Anastasia Stamatopoulou

ADAM12s in maternal serum as a potential marker of pre-eclampsia.

To examine whether maternal serum ADAM12s, a potential first‐ and second‐trimester marker of fetal aneuploidy and fetal growth, had altered concentrations in the first or second trimester of pregnancies subsequently developing pre‐eclampsia.

PAPP‐A and free ß‐hCG stability in first trimester serum using PerkinElmer AutoDELFIA® and DELFIA® Xpress systems

In this study we aim to investigate the stability of free‐β‐hCG and PAPP‐A over time in serum and whole blood in typical routine temperatures.

First‐trimester placental growth factor as a marker for hypertensive disorders and SGA

The objective of this study was to examine first‐trimester maternal serum placental growth factor (PlGF) levels in pregnancies which later develop hypertensive and growth complications.

The impact of fetal gender on first trimester nuchal translucency and maternal serum free β-hCG and PAPP-A MoM in normal and trisomy 21 pregnancies

To investigate if fetal sex has an impact on 1st trimester combined screening for aenuploidy.

Maternal serum ADAM12s in the late first trimester of pregnancies with Trisomy 21.

ADAM12s is a placenta‐derived glycoprotein that is involved in growth and differentiation, and has been shown to be a potential first‐trimester and second‐trimester marker of Trisomy 21 and other aneuploides. Maternal ADAM12s concentrations show a considerable temporal variation with gestational age and here we study the levels at 11–13 weeks of gestation to establish the effectiveness or otherwise at a time when other established markers are used.

First trimester maternal serum placental growth factor in trisomy 21 pregnancies

To examine placental growth factor (PlGF) levels in first trimester maternal serum in trisomy 21 pregnancies and to investigate the potential value of PlGF in a first trimester screening test.

Placental Protein-13 and Pregnancy- Associated Plasma Protein-A as First Trimester Screening Markers for Hypertensive Disorders and Small for Gestational Age Outcomes

Objective. To investigate the role of placenta protein 13 (PP13) and pregnancy-associated plasma protein-A (PAPP-A) in hypertensive disorders and small for gestational age (SGA) during first trimester of pregnancy. Methods. In this case–control study, first trimester serum samples (11+0 to 13+6 weeks) were retrieved from frozen storage of which 452 were from normal pregnancies and 47 samples were identified to have pregnancies with at least one of the following adverse outcomes: SGA, preeclampsia (PE), hemolysis, elevated liver enzymes, and low platelets (HELLP), or gestational hypertension (GH). PP13 concentrations were measured by a new AutoDELFIA method. Levels of PAPP-A were measured for a first trimester screening program using Kryptor analyzer. Results. First trimester levels of PAPP-A are significantly lower in cases of SGA, PE, and most subgroups including HELLP. Levels of PP13 were not found to differ between control and affected pregnancies. Conclusion. PP13 needs to be studied further as our results contrast the majority of previous studies.

The stability of free-β human chorionic gonadotrophin and pregnancy-associated plasma protein-A in first trimester dried blood spots†

To determine the stability of first trimester free‐β human chorionic gonadotrophin (free‐β hCG) and pregnancy‐associated plasma protein‐A (PAPP‐A) in dried blood spots (DBSs) under typical storage conditions.

Is maternal renal disease a cause of elevated free β-hCG in first trimester aneuploidy screening?

To asses whether supra elevated levels of maternal serum free beta hCG in the first trimester are associated with impaired renal function.

Maternal plasma levels of follistatin‐related gene protein in the first trimester of pregnancies with Down syndrome

To determine maternal plasma levels of follistatin‐related gene protein (FLRG) in the first trimester of pregnancy and assess its potential role as a marker for prenatal screening of Down syndrome.